"Multidrug-resistant tuberculosis" from_date:2012

1,152 resultsPro users have access to +292 Systematic Reviews

Filter Results
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
                    • Pro

                            Clinical Area Pro

                            Further Refinement
                            User Guide

                            User Guide

                            1
                            2024PLoS ONE
                            Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini. We compared the cost-consequence of a home-based multidrug-resistant tuberculosis (MDR-TB) model of care, based on task-shifting of directly observed therapy (DOT) and MDR-TB injection administration to lay health workers, to a routine clinic-based strategy within
                            2
                            2024PLoS ONE
                            Determinants of sputum culture conversion time in multidrug-resistant tuberculosis patients in ALERT comprehensive specialized hospital, Addis Ababa, Ethiopia: A retrospective cohort study. The treatment response of multi-drug resistance tuberculosis (MDR-Tuberculosis) patients is mainly dictated by the sputum culture conversion. An earlier culture conversion is a remarkable indicator
                            Subscribe to Trip PRO for an enhanced experience
                            • Access to millions of Full-text articles where avaliable
                            • Unlock 100,000+ extra articles with Systematic Reviews
                            • Further Filtering Options
                            • No adverts
                            • Advanced Search Ability
                            • Enhanced SmartSearch showing unlimited related articles
                            Read more about Trip PRO
                            3
                            2024PLoS ONE
                            Whole Genome Sequencing of Mycobacterium tuberculosis under routine conditions in a high-burden area of multidrug-resistant tuberculosis in Peru. Whole Genome Sequencing (WGS) is a promising tool in the global fight against tuberculosis (TB). The aim of this study was to evaluate the use of WGS in routine conditions for detection of drug resistance markers and transmission clusters in a multidrug
                            4
                            2024NEJM
                            Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam. Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating infection among contacts of persons with drug-resistant tuberculosis are lacking. We conducted a double-blind, randomized, controlled trial comparing 6 months of daily levofloxacin (weight
                            5
                            Patch Test-Positive Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Due to Cycloserine in Multidrug-Resistant Tuberculosis: A Case Report with a Review of the Literature. Antitubercular treatment (ATT) is associated with multiple cutaneous adverse drug reactions. Second-line ATT is also associated with numerous adverse reactions; however, cutaneous reactions are under-reported . Oral drug provocation (ODP) in multidrug-resistant tuberculosis is challenging because of the paucity of time and the risk of developing secondary drug resistance in the case of interrupted medication. In this paper, we report a case of drug reaction with eosinophilia and systemic symptoms caused by cycloserine in an 18-year-old girl, which was confirmed with ODP and a patch test.
                            6
                            2025Emerging Infectious Diseases
                            Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment. High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using
                            7
                            2025BMC Infectious Diseases
                            Evaluation of a modified short all oral treatment regimen for rifampicin-multidrug resistant tuberculosis in Dominican Republic. This study aims to evaluate the effectiveness, safety, and impact on health-related quality of life (HQoL) of a fully oral shortened regimen for Rifampicin-Resistant/Multidrug-Resistant Tuberculosis (RR/MDR-TB) over 9 to 12 months under programmatic conditions
                            8
                            2025Pediatric Research
                            Global burden of multidrug-resistant tuberculosis in children and adolescents. Multidrug-resistant tuberculosis (MDR-TB) has become a major global public health issue, which has worsened over time owing to changes in disease-related trends. This study aimed to determine global trends in MDR-TB among children and adolescents for strategic health planning. A secondary analysis was performed on MDR
                            9
                            2025Clinical Infectious Diseases
                            Lower Tuberculosis Incidence Among People With Human Immunodeficiency Virus Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. Evidence shows that isoniazid preventive therapy (IPT) reduces tuberculosis (TB) incidence among people with human immunodeficiency virus (HIV) with additive benefit beyond
                            10
                            2023PLoS ONE
                            The Targeted Maximum Likelihood estimation to estimate the causal effects of the previous tuberculosis treatment in Multidrug-resistant tuberculosis in Sudan. This study used Targeted Maximum Likelihood Estimation (TMLE) as a double robust method to estimate the causal effect of previous tuberculosis treatment history on the occurrence of multidrug-resistant tuberculosis (MDR-TB). TMLE
                            11
                            2023PLoS ONE
                            Predictors of multidrug-resistant tuberculosis in a teaching hospital in Ghana: A case-control study. Multidrug-resistant Tuberculosis (MDR-TB) remains a global health concern. The disease results in a prolonged treatment and hence, poses a financial burden to affected individuals and their families. The Ghana National TB Control Programme (NTP) has made extensive efforts to control the menace
                            12
                            2023PLoS ONE
                            Addressing patients' unmet needs related to multidrug-resistant tuberculosis (MDR-TB) care: A qualitative research study from Pune city, India. We aimed to identify and describe the unmet needs of patients with multidrug-resistant tuberculosis (MDR-TB). As a part of larger cross-sectional mixed-methods (qualitative and quantitative data) study on pathways to MDR-TB care, here we present
                            13
                            Second-line anti-tuberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment. This study aimed to investigate the association between drug exposure and adverse events (AEs) during the standardized multidrug-resistant tuberculosis (MDR-TB) treatment, as well as to identify predictive drug exposure thresholds. We conducted a prospective
                            14
                            2024Emerging Infectious Diseases
                            Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia. Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and adherence. The report highlights the risk
                            15
                            Transmission of Fluoroquinolones Resistance among Multidrug-Resistant Tuberculosis in Shanghai, China: A Retrospective population-based Genomic Epidemiology Study. Fluoroquinolones (FQ) are essential for the treatment of multidrug-resistant tuberculosis (MDR-TB). The FQ resistance (FQ-R) rate in MDR-TB in China and its risk factors remain poorly understood. We conducted a retrospective
                            16
                            2024BMC Infectious Diseases
                            Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China. Multidrug-resistant tuberculosis (MDR-TB) is a global health threat associated with high morbidity and mortality rates. Diagnosis and treatment delays are associated with poor treatment outcomes in patients with MDR-TB. However, the risk factors associated
                            17
                            Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia. Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify
                            18
                            2024PLOS global public health
                            Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. The impact of HIV viral suppression on multidrug resistant tuberculosis (MDR-TB) treatment outcomes among people with HIV (PWH) has not been clearly established. Using secondary data from a cluster-randomized clinical trial among people with MDR-TB in South Africa, we examined the effects of HIV
                            19
                            2024Trials
                            A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has
                            20
                            2024BMC Infectious Diseases
                            Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019. Tuberculosis(TB) remains a pressing public health challenge, with multidrug-resistant tuberculosis (MDR-TB) emerging as a major threat. And healthcare authorities require reliable epidemiological evidence as a crucial reference to address this issue effectively. The aim was to offer a comprehensive